Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LiPlaCis · 1 trial · 2 indications
Primary Objective: Assessment of adverse events and laboratory abnormalities
| Arm | Type | Description |
|---|---|---|
| LiPlaCis | EXPERIMENTAL | Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug. |
| Name | Type | Description |
|---|---|---|
| LiPlaCis | DRUG | LiPlaCis IV every 3 weeks on day 1, day 8 |
Inclusion Criteria: * Histological or cytological documented locally advanced or metastatic solid tumour relapsed on 2 or more different prior therapies. From step 5 and extension phase, population limited to Skin Cancer patients (non screened) or metastatic Breast Cancer patients or metastatic cas...
LiPlaCis is an investigational small molecule being studied for the treatment of advanced or refractory solid tumours. It is in Phase 1 clinical development for this indication, with a completed Phase I/II trial that also included Phase 2 parts for metastatic breast cancer, prostate cancer, and skin cancer.
LiPlaCis is being developed by Allarity Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker ALLR. The company is conducting clinical research on this investigational oncology drug.
LiPlaCis is in Phase 1 clinical development for advanced or refractory solid tumours. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and tolerability.
LiPlaCis has one completed clinical trial, NCT01861496, titled "Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours." This trial enrolled 50 participants in Denmark and was an uncontrolled, non-randomized study.
LiPlaCis is the drug name used in clinical development by Allarity Therapeutics. No alternative names for this drug have been disclosed in the available clinical trial information.